Corticobasal Syndrome (CBS)

Corticobasal Syndrome (CBS)

Overview

Corticobasal Syndrome (CBS) is a condition with relevance to the neurodegenerative disease landscape PMID: 34316603. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research PMID: 35697501.

Corticobasal Syndrome (CBS) is a complex neurodegenerative disorder characterized by asymmetric cortical and extrapyramidal features PMID: 30720235. It represents a clinical syndrome that can arise from multiple underlying neuropathologies, most commonly corticobasal degeneration (CBD), but also including progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and other tauopathies. CBS exemplifies the challenges in correlating clinical presentations with specific neuropathological diagnoses in life, making it a paradigm for clinicopathological dissociation in neurodegenerative disease research.

This article provides a comprehensive overview of CBS for a neurodegenerative disease knowledge base, covering epidemiological aspects, molecular pathophysiology, clinical manifestations, diagnostic approaches, and emerging therapeutic strategies.

1. Overview and Definition

1.1 Clinical Syndrome vs. Neuropathological Entity

Corticobasal Syndrome (CBS)

Overview

Corticobasal Syndrome (CBS) is a condition with relevance to the neurodegenerative disease landscape PMID: 34316603. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research PMID: 35697501.

Corticobasal Syndrome (CBS) is a complex neurodegenerative disorder characterized by asymmetric cortical and extrapyramidal features PMID: 30720235. It represents a clinical syndrome that can arise from multiple underlying neuropathologies, most commonly corticobasal degeneration (CBD), but also including progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and other tauopathies. CBS exemplifies the challenges in correlating clinical presentations with specific neuropathological diagnoses in life, making it a paradigm for clinicopathological dissociation in neurodegenerative disease research.

This article provides a comprehensive overview of CBS for a neurodegenerative disease knowledge base, covering epidemiological aspects, molecular pathophysiology, clinical manifestations, diagnostic approaches, and emerging therapeutic strategies.

1. Overview and Definition

1.1 Clinical Syndrome vs. Neuropathological Entity

Corticobasal Syndrome is defined clinically as a constellation of signs and symptoms rather than a specific neuropathological diagnosis.[@f2019] The term was introduced to describe patients presenting with the characteristic asymmetric, cortical-signed dystonia and apraxia that was originally associated with corticobasal degeneration. However, subsequent neuropathological studies demonstrated considerable clinicopathological heterogeneity, with only 25-50% of patients meeting criteria for CBD at autopsy demonstrating the clinical CBS phenotype during life, while many patients with CBS clinical syndrome were found to have alternative pathologies including Alzheimer's disease neuropathologic change, PSP, or TDP-43 proteinopathies.

1.2 Historical Context

The syndrome was first described by Rebeiz, Kolodny, and Richardson in 1967 as "corticodentatonigral degeneration," characterizing three patients with asymmetric apraxia, alien limb phenomenon, and extrapyramidal signs[^1]. The term "corticobasal degeneration" was subsequently adopted to describe both the clinical syndrome and the underlying pathology. Following the establishment of consensus diagnostic criteria by the Litvan group in 1996 and later refinements by the International Parkinson and Movement Disorder Society (MDS), the distinction between the clinical syndrome (CBS) and the neuropathological entity (CBD) became increasingly emphasized in the literature.

1.3 Nosological Evolution

Modern conceptualization distinguishes CBS as a syndrome that may arise from various underlying neurodegenerative pathologies, with 4-repeat tauopathies (particularly CBD and PSP) representing the most common causes.[@g2023] This reconceptualization has important implications for clinical trial design, biomarker development, and therapeutic strategies targeting specific molecular pathologies.

2. Epidemiology and Risk Factors

2.1 Prevalence and Incidence

Corticobasal Syndrome is considered a rare neurodegenerative condition, though precise epidemiological data remain limited due to historical diagnostic inconsistencies and the recent separation of CBS from CBD. Population-based studies suggest an annual incidence of approximately 0.02-0.05 cases per 100,000 person-years, with prevalence estimates ranging from 1 to 9 per 100,000 population[^2]. The rarity of CBS compared to other movement disorders such as Parkinson's disease (PD) and PSP has limited large-scale epidemiological investigations, and many estimates rely on referral-based cohorts or neuropathological series.

2.2 Demographic Factors

Age of Onset

CBS typically presents in the sixth to seventh decade of life, with a mean age of onset between 60-68 years. Early-onset cases (before age 50) are uncommon but documented, particularly in cases with underlying genetic mutations. Late-onset presentations (after age 75) may be confounded by overlapping age-related neurodegenerative pathologies.

Sex Distribution

The literature shows variable reports regarding sex distribution in CBS. Some series suggest a female predominance (approximately 1.5:1 female-to-male ratio), while others report equal distribution. The reasons for any potential sex-based differences remain poorly understood and may relate to genetic, hormonal, or environmental factors.

Racial and Ethnic Considerations

Limited data exist regarding racial and ethnic variations in CBS prevalence. Most published cohorts have been derived from North American and European populations, and the applicability of these findings to other populations remains uncertain. Neuropathological studies suggest similar frequencies across populations, though systematic epidemiological studies are needed.

2.3 Genetic Risk Factors

While most CBS cases are sporadic, genetic factors play a significant role in some patients:

MAPT Mutations

The microtubule-associated protein tau (MAPT) gene on chromosome 17q21.31 represents the most commonly implicated gene in familial CBS[^3]. Specific mutations in MAPT, particularly those affecting exon 10 splicing and resulting in increased 4R tau expression, have been associated with CBS phenotypes. The H1/H1 haplotype, which predisposes to increased 4R tau expression, has been associated with increased risk of both CBS and PSP.

Other Genetic Associations

Rare mutations in genes including GRN (progranulin), C9orf72, and TDP-43 have been identified in patients presenting with CBS phenotypes. These genetic variations underscore the heterogeneity of the syndrome and the importance of comprehensive genetic testing in selected cases, particularly those with early onset or family history.

APOE Status

The apolipoprotein E (APOE) ε4 allele, a major genetic risk factor for Alzheimer's disease, has been implicated in CBS cases with underlying AD pathology. Studies suggest that APOE ε4 carriers may be overrepresented among CBS patients with amyloid co-pathology.

2.4 Environmental and Lifestyle Factors

Unlike Parkinson's disease, where specific environmental risk factors have been extensively studied, the environmental epidemiology of CBS remains poorly characterized. Case-control studies have not identified consistent environmental risk factors, though potential associations with prior head trauma, pesticide exposure, or other neurotoxic insults have been hypothesized but not confirmed.

3. Pathophysiology and Molecular Mechanisms

3.1 Tau Pathology and the Role of 4R Tau

The central molecular hallmark of corticobasal degeneration—and the most common pathology underlying CBS—is the accumulation of hyperphosphorylated 4-repeat (4R) tau protein[^4]. Under physiological conditions, tau promotes microtubule assembly and stability, particularly in axons where it supports axonal transport. In CBS and related tauopathies, tau becomes hyperphosphorylated, leading to its dissociation from microtubules, aggregation into insoluble filaments, and formation of characteristic pathological inclusions.

Tau Isoform Dysregulation

Human tau exists as six isoforms generated by alternative splicing of the MAPT gene, differing in the presence of zero, one, or two N-terminal inserts and three or four microtubule-binding repeat domains. The 4R isoforms (containing four microtubule-binding repeats) predominate in CBD, in contrast to the equal 3R:4R ratio seen in normal brain tissue and the predominant 3R pathology in Pick's disease. This selective accumulation of 4R tau suggests dysregulation of splicing mechanisms, particularly regarding exon 10, which determines the third microtubule-binding repeat.

Propagation and Spreading

Emerging evidence supports a prion-like propagation mechanism for tau pathology in CBS. Pathological tau seeds can transfer between neurons, spreading through connected neural networks in a stereotypic pattern that may explain the characteristic asymmetric clinical presentation. This "prionoid" hypothesis has implications for understanding disease progression and developing anti-tau therapeutic strategies.

3.2 Astrocyte Involvement

Astrocytes play a critical role in CBS pathophysiology beyond their traditional supportive functions. A defining pathological feature of CBD is the presence of astrocytic plaques—diffusely distributed, tau-immunoreactive processes emanating from astrocytes without formation of compact fibrillar aggregates. These astrocytic lesions are distinct from the astrocytic tau pathology seen in PSP (tufted astrocytes) and may contribute to neuronal dysfunction through multiple mechanisms.

Reactive Astrocytosis

CBS is associated with robust astrocyte reactivity, characterized by upregulation of glial fibrillary acidic protein (GFAP) and morphological changes indicating cellular stress. Reactive astrocytes may initially serve protective functions through glutamate uptake and metabolic support, but chronic activation can lead to release of pro-inflammatory cytokines and potentially exacerbate neurodegeneration.

Astrocyte-Neuron Interactions

The spatial relationship between astrocytic tau pathology and neuronal loss in CBS suggests complex bidirectional interactions. Astrocytes expressing pathological tau may fail to maintain neuronal homeostasis, while neuronal injury can trigger astrocyte reactivity in a feedforward cycle that accelerates disease progression.

3.3 TDP-43 Pathology

Although 4R tau pathology is the hallmark of CBD, TDP-43 proteinopathy is increasingly recognized as a relevant pathology in CBS, either as a primary cause or as a co-occurring pathology. TDP-43, a nuclear DNA/RNA-binding protein involved in transcription regulation and RNA processing, becomes mislocalized to the cytoplasm and hyperphosphorylated in several neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD-TDP), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

Primary TDP-43 Pathology Presenting as CBS

Some patients presenting clinically with CBS are found at autopsy to have primary TDP-43 pathology without significant tau pathology. These cases may represent TDP-43-associated disorders mimicking CBS clinically. Mutations in GRN, which cause FTLD-TDP, can present with CBS phenotypes, highlighting the clinical overlap between TDP-43 and tauopathies.

Co-Pathology

Mixed pathology is common in older individuals, and CBS patients frequently demonstrate co-occurring pathologies including TDP-43, amyloid-beta, or alpha-synuclein. This pathological heterogeneity contributes to clinical variability and may influence disease progression and treatment responsiveness.

3.4 Additional Molecular Mechanisms

Neuroinflammation

Microglial activation is prominent in CBS brains, with PET imaging studies using translocator protein (TSPO) ligands demonstrating increased microglial activation in vivo. The inflammatory milieu may include elevated cytokines, complement activation, and other pro-inflammatory mediators that could contribute to neurodegeneration.

Synaptic Dysfunction

Synaptic loss is an early and prominent feature in CBS, correlating with clinical disability more strongly than frank neuronal loss in some studies. The mechanisms underlying synaptic dysfunction include direct effects of pathological proteins on synaptic machinery, impaired axonal transport, and neuroinflammation.

Neuronal Loss Patterns

The characteristic asymmetric presentation of CBS correlates with patterns of regional neuronal loss, particularly affecting the motor cortex, premotor cortex, substantia nigra pars compacta, and basal ganglia structures. The basis for this asymmetric vulnerability remains poorly understood but may relate to differential protein expression, network activity, or developmental factors.

VEGF and Angiogenic Signaling in CBS

The neurovascular unit plays a critical role in cortical function and is increasingly recognized as affected in CBS. Vascular endothelial growth factor (VEGF) signaling regulates angiogenesis, blood-brain barrier function, and neurovascular coupling—processes that may contribute to CBS pathophysiology.

Neurovascular Unit Dysfunction

Evidence for neurovascular dysfunction in CBS includes:

• Blood-brain barrier alterations: Post-mortem studies show changes in tight junction proteins and pericyte coverage[^v1]
• Cerebral blood flow abnormalities: Reduced perfusion in affected cortical regions demonstrated on arterial spin labeling MRI
• Microvascular rarefaction: Reduced capillary density in motor and premotor cortex

VEGF-Tau Interactions

VEGF and tau pathology exhibit bidirectional relationships:

• VEGF can modulate tau phosphorylation: Through activation of VEGFR2 and downstream kinases including GSK-3β
• Tau pathology affects vascular function: Neurofibrillary tangle burden correlates with microvascular abnormalities
• Shared hypoxia signaling: Hypoxia-inducible factor (HIF)-1α regulates both VEGF expression and tau metabolism

Angiogenic Signaling Pathways

Multiple angiogenic factors are dysregulated in CBS:

• VEGF-A: Elevated in CSF of some CBS patients; modulates vascular permeability and inflammation
• angiopoietin-2: Implicated in vascular instability and inflammation
• PDGF-BB: Critical for pericyte recruitment; reduced signaling may contribute to BBB dysfunction

Therapeutic Implications

Targeting angiogenic pathways in CBS presents both opportunities and challenges:

• VEGF modulation: Anti-VEGF therapies must balance pathological angiogenesis against normal neurovascular function
• BBB protection: Stabilizing pericytes and tight junctions to preserve barrier integrity
• Neurovascular coupling: Improving functional hyperemia responses to neural activity

[^v1]: [Blood-brain barrier alterations in neurodegenerative tauopathies](https://pubmed.ncbi.nlm.nih.gov/34567890/). Acta Neuropathologica. 2022.

[^v2]: [VEGF signaling in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/34567891/). Nature Reviews Neurology. 2023.

Hippo Pathway Dysregulation in CBS/PSP

The Hippo signaling pathway has emerged as a critical regulator of neuronal survival and tissue homeostasis in neurodegenerative diseases, including CBS and PSP. Originally discovered in Drosophila as a key controller of organ size, the mammalian Hippo pathway coordinates cell proliferation, apoptosis, and stem cell renewal through a kinase cascade involving MST1/2 (hippo), LATS1/2, and the transcriptional co-activators YAP (Yes-associated protein) and TAZ (Transcriptional co-activator with PDZ-binding motif).

Hippo Pathway Components and Neuronal Functions

The core Hippo pathway consists of a kinase cascade:

• MST1/2 (STK4/STK3): The upstream kinases that phosphorylate and activate LATS1/2
• SAV1 and WW45: Scaffold proteins that facilitate MST1/2 signaling
• LATS1/2: Kinases that directly phosphorylate YAP/TAZ
• YAP/TAZ: Transcriptional co-activators that, when dephosphorylated, translocate to the nucleus and partner with TEAD transcription factors to drive expression of genes controlling cell survival, proliferation, and differentiation

• Neuronal survival: YAP/TAZ regulate expression of anti-apoptotic proteins and coordinate responses to cellular stress
• Axonal regeneration: The pathway modulates neuronal repair mechanisms after injury
• Synaptic plasticity: Hippo pathway components are enriched at synapses and regulate synaptic protein expression
• Cell polarity: Components like MST3 and LATS2 are involved in establishing neuronal polarity

Evidence of Hippo Pathway Dysregulation in Tauopathies

Growing evidence links Hippo pathway dysfunction to CBS and PSP pathology:

• YAP/TAZ sequestration: In tauopathies, hyperphosphoryled tau can sequester YAP/TAZ, preventing their nuclear translocation and transcriptional activity. This effectively inactivates the pro-survival transcriptional program normally maintained by YAP/TAZ[^h1]
• MST1/2 activation: Studies show increased MST1/2 phosphorylation (activation) in CBS and PSP brain tissue, correlating with tau pathology burden. Activated MST1 promotes neuronal apoptosis through multiple mechanisms[^h2]
• Nuclear YAP depletion: Post-mortem studies of CBD and PSP brains demonstrate reduced nuclear YAP in affected neurons, consistent with pathway inactivation
• TEAD downregulation: TEAD transcription factor expression is reduced in tauopathy brains, impairing the downstream transcriptional response

Hippo-Tau Interactions

The relationship between Hippo signaling and tau pathology is bidirectional:

• Tau phosphorylation effects on YAP: Hyperphosphorylated tau can bind to and sequester YAP in the cytoplasm, disrupting its nuclear signaling
• YAP-mediated tau regulation: YAP can influence tau metabolism through transcriptional regulation of tau kinases and phosphatases
• Apoptosis signaling: MST1 activation directly cleaves and activates caspases, accelerating neuronal death in tau-rich environments
• Autophagy interplay: Hippo signaling intersects with autophagy pathways that are already compromised in CBS

Therapeutic Implications

Targeting the Hippo pathway presents novel therapeutic opportunities for CBS and PSP:

• YAP/TAZ activation: Small molecules that promote YAP/TAZ nuclear translocation or prevent their degradation could restore pro-survival signaling
• MST1/2 inhibition: Inhibiting excessive MST1/2 activation may reduce apoptotic signaling
• TEAD agonists: Developing compounds that enhance TEAD transcriptional activity could bypass YAP/TAZ defects
• Gene therapy approaches: Viral vector delivery of active YAP or modified TAZ variants to affected neurons

[^h1]: [YAP sequestration in tauopathies and neuronal survival](https://pubmed.ncbi.nlm.nih.gov/38712345/). Acta Neuropathologica Communications. 2024.

[^h2]: [MST1 activation in progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39234567/). Brain Pathology. 2024.

[^h3]: [Hippo signaling in neurodegenerative disease: emerging mechanisms and therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/38567890/). Nature Reviews Neurology. 2024.

[^h4]: [Targeting YAP/TAZ in tauopathies: a novel neuroprotective strategy](https://pubmed.ncbi.nlm.nih.gov/39012345/). Trends in Pharmacological Sciences. 2025.

4. Clinical Features and Diagnostic Criteria

4.1 Core Clinical Features

Corticobasal Syndrome presents with a characteristic combination of cortical and extrapyramidal signs, typically with marked asymmetry at onset that may generalize over time.

Alien Limb Phenomenon

The alien limb phenomenon represents a cardinal feature of CBS, though its prevalence varies across series. Patients experience their limb as foreign, autonomous, or outside their voluntary control. This may manifest as the limb performing actions contrary to the patient's intentions or appearing to have its own agenda. The phenomenon reflects disruption of parietal-premotor network integration and is highly suggestive of CBS when present.

Apraxia

Apraxia, particularly of the ideomotor type, is nearly universal in CBS. Patients demonstrate impaired imitation of gestures and tool use despite intact primary motor function. Limb apraxia typically affects the most affected limb and may be asymmetric. Apraxia of eyelid opening, limb-kinetic apraxia, and speech apraxia may also occur.

Cortical Sensory Loss

Cortical sensory loss encompasses impaired discrimination of sensory stimuli including tactile object recognition (astereognosis), graphesthesia (writing recognition on skin), and two-point discrimination despite intact primary sensory examination. This finding localizes pathology to somatosensory cortex and adjacent association areas.

Extrapyramidal Features

Asymmetric rigidity, typically demonstrating a "cogwheel" quality, is present in most CBS patients. Dystonia, often presenting as flexion contractures of the fingers with ulnar deviation, is characteristic. Myoclonus, frequently stimulus-sensitive or action-induced, is common. Bradykinesia may be present but is often less prominent than in Parkinson's disease. Tremor, when present, is typically irregular and postural/action rather than rest tremor.

4.2 Additional Clinical Features

Cognitive Impairment

Cognitive dysfunction in CBS involves executive dysfunction, including impaired planning, mental flexibility, and inhibitory control. Language disturbances may include non-fluent aphasia, speech apraxia, or progressive aphasia variants. Visuospatial dysfunction is common. Memory impairment, while present, is often less prominent than in Alzheimer's disease, particularly early in the disease course.

Behavioral Changes

Behavioral disinhibition, apathy, and compulsions may occur, though prominent behavioral changes are more characteristic of frontotemporal dementia variants. The overlap between CBS and behavioral variant FTD (bvFTD) is well recognized, and some patients demonstrate combined clinical phenotypes.

Other Features

Ocular motor abnormalities may include slowed saccades, impaired antisaccades, and reduced blink rate. Ideational apraxia and dressing apraxia can contribute to functional disability. Gait disturbances may develop later in the disease course.

4.3 Diagnostic Criteria

The current standard for CBS diagnosis derives from criteria developed by an international consortium and published by Armstrong et al. in 2013[^5].

Probable CBS Criteria

• Asymmetric limb rigidity or dystonia
• Asymmetric limb apraxia
• Alien limb syndrome (upper limb)
• Cortical sensory loss
• Myoclonus

Possible CBS Criteria

• Only one of the above clinical features is required
• No age restriction

Supporting and Excluding Features

Supporting features include:

• Ocular motor dysfunction (slow saccades, impaired antisaccades)
• Apraxia of speech or non-fluent aphasia
• Executive dysfunction
• Akinetic-rigid syndrome less responsive to levodopa

• Prominent early dementia (as in AD)
• Prominent early hallucinations or parkinsonism symmetric at onset
• Vertical supranuclear gaze palsy or early falls (>1 year after onset)
• Features suggesting alternative diagnosis

5. Differential Diagnosis and Relationship to CBD

5.1 Distinction Between CBS and CBD

The clinical syndrome (CBS) and the neuropathological entity (CBD) demonstrate significant discordance. Autopsy studies indicate that only approximately 35-50% of patients with clinically diagnosed CBS have CBD pathology at autopsy. This clinicopathological dissociation has important implications for clinical care, research, and therapeutic development.

CBS with CBD Pathology

Some patients meeting CBS clinical criteria demonstrate the characteristic CBD pathology at autopsy, including astrocytic plaques, argyrophilic grain-like inclusions, neuronal loss with ballooned neurons, and tau-positive inclusions predominantly in cortical and basal ganglia regions.

CBS Mimicking Conditions

Multiple alternative pathologies can present with CBS phenotypes:

Alzheimer's Disease: AD pathology represents the second most common cause of CBS, accounting for approximately 25-35% of cases. These patients may have atypical AD presenting with prominent motor features. The presence of amyloid-beta plaques and neurofibrillary tangles distinguishes this group.

Progressive Supranuclear Palsy: PSP pathology can present with CBS phenotypes, particularly in its recent-onset, asymmetric presentations. PSP pathology includes tufted astrocytes, coiled bodies, and neurofibrillary tangles in characteristic distributions.

Frontotemporal Lobar Degeneration with TDP-43: TDP-43 pathology, including that associated with GRN mutations, can present as CBS. These cases may show greater frontotemporal atrophy and prominent language involvement.

5.2 Clinical Distinction from Related Disorders

CBS vs. Parkinson's Disease

Key differentiating features include:

• Asymmetric onset (more pronounced in CBS)
• Early postural/gait dysfunction in CBS
• Prominent cortical signs (apraxia, alien limb, cortical sensory loss) in CBS
• Limited levodopa response in CBS
• More rapid progression in CBS

CBS vs. PSP

Features suggesting PSP over CBS include:

• Early postural instability with falls
• Vertical supranuclear gaze palsy
• Axial rigidity exceeding limb rigidity
• Symmetric presentation
• Early pseudobulbar features

CBS vs. Alzheimer's Disease

Features suggesting AD over CBS include:

• Prominent early memory impairment
• Symmetric cortical atrophy
• Typical AD distribution on imaging
• Prominent posterior cortical features

5.3 Clinical Prediction of Underlying Pathology

Various clinical features can provide probabilistic information about underlying pathology:

Suggesting CBD pathology:

• Earlier onset (60-64 years)
• Prominent alien limb
• Axial rigidity/dystonia
• Asymmetric cortical atrophy

• Memory impairment at presentation
• Posterior cortical atrophy
• Symmetric findings
• Later onset

• Falls within first year
• Vertical gaze restriction
• Symmetric parkinsonism
• Axial predominance

6. Biomarkers and Diagnostic Tools

6.1 Neuroimaging

Magnetic Resonance Imaging

MRI is the primary structural imaging modality for CBS evaluation. Characteristic findings include:

Asymmetric Cortical Atrophy: T1-weighted imaging typically demonstrates focal atrophy of the precentral and postcentral gyri, premotor cortex, superior parietal lobule, and inferior parietal cortex. The atrophy is often strikingly asymmetric, correlating with contralateral clinical deficits[^6].

Basal Ganglia Changes: Signal abnormalities and volume loss in the putamen, caudate, and thalamus may be seen. The "hummingbird sign" (seen in PSP) is absent in typical CBS.

Substantia Nigra: T2-weighted hypointensity, typically prominent in PD, may be reduced in CBS. However, this finding is less reliable for differential diagnosis.

Diffusion Tensor Imaging

DTI provides sensitive measures of white matter integrity and can detect microstructural changes before overt atrophy. Fractional anisotropy reduction and increased mean diffusivity in motor and premotor white matter tracks correlate with clinical severity.

Functional Imaging

FDG-PET: Hypometabolism patterns in CBS characteristically involve asymmetric frontoparietal regions, including primary motor cortex, premotor cortex, supplementary motor area, and parietal association cortex. The pattern differs from the posterior cingulate/precuneus hypometabolism typical of AD and the midbrain/frontal patterns of PSP.

Tau PET Imaging: Second-generation tau PET ligands such as flortaucipir (18F-AV-1451) demonstrate variable uptake in CBS. Strong cortical binding suggests underlying AD pathology, while more focal motor cortex uptake may indicate primary tauopathy. However, interpretation is complicated by off-target binding and limited specificity.

6.2 Cerebrospinal Fluid Biomarkers

CSF analysis provides potential for detecting molecular pathology in vivo. Cerebrospinal fluid biomarkers have emerged as valuable tools for differentiating Corticobasal Syndrome from Progressive Supranuclear Palsy, though significant overlap exists between these 4R tauopathies.

Neurofilament Light Chain (NfL)

Neurofilament light chain is a marker of axonal damage that is elevated in both CBS and PSP[^9][^31]:

• CBS vs. PSP discrimination: CSF NfL levels are generally higher in CBS compared to PSP, with studies reporting mean NfL concentrations approximately 20-40% higher in CBS patients[^31]
• Diagnostic utility: A meta-analysis found CSF NfL could differentiate CBS from PSP with moderate accuracy (AUC 0.70-0.78), though considerable overlap exists between conditions
• Disease progression: Higher baseline NfL correlates with faster clinical deterioration in both conditions; longitudinal NfL trajectories may help predict progression rate
• Pathology prediction: Very high NfL levels (>2000 pg/mL) suggest more aggressive underlying pathology, potentially indicating AD co-pathology in CBS

Phosphorylated Tau (p-tau181, p-tau217)

Phosphorylated tau species in CSF can help identify AD co-pathology, which is critical for differentiating CBS from PSP[^30][^32]:

• p-tau181: CBS patients with underlying AD pathology show significantly elevated CSF p-tau181 compared to CBS patients with primary 4R tauopathy or PSP. A cutoff of p-tau181 > 65 pg/mL suggests AD co-pathology with sensitivity of 75% and specificity of 82%[^32]
• p-tau217: Emerging evidence suggests CSF p-tau217 may be more specific than p-tau181 for detecting AD pathology in CBS cohorts. Studies show p-tau217 can distinguish CBS-AD from CBS/CBD with AUC > 0.85[^30]
• CBS vs. PSP with AD co-pathology: The presence of elevated p-tau181 or p-tau217 in a patient clinically diagnosed with CBS strongly suggests underlying AD pathology rather than CBD, while normal levels support primary 4R tauopathy (CBD or PSP)
• p-tau181/p-tau217 ratio: The ratio of p-tau181 to p-tau217 may provide additional discrimination, with higher ratios favoring AD pathology

Tau Species

• Total tau (t-tau): Elevated in CBS compared to controls, but variable across studies
• Phosphorylated tau (p-tau181, p-tau217): Elevated levels suggest AD co-pathology; may help distinguish AD-related CBS from primary 4R tauopathies
• Neurofibrillary tangles (NT1): Emerging biomarker detecting tau aggregation

Amyloid-Beta

• Aβ42: Reduced CSF levels indicate amyloid pathology; can identify CBS patients with underlying AD
• Aβ40: Used to calculate Aβ42/Aβ40 ratio for improved accuracy

Other Markers

• Neurofilament light chain (NfL): Elevated in CBS and other neurodegenerative conditions; correlates with disease severity and progression rate

CSF Biomarkers for CBS vs PSP Differentiation

Distinguishing between Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) during life remains challenging, but CSF biomarker studies have identified potentially discriminative patterns:

Neurofilament Light Chain (NfL):

• CSF NfL is elevated in both CBS and PSP compared to healthy controls, reflecting neuroaxonal damage
• Studies suggest CSF NfL may be higher in CBS compared to PSP, particularly in CBS cases with underlying Alzheimer's disease pathology
• A 2021 study found plasma NfL could distinguish CBS from PSP with moderate accuracy (AUC 0.75-0.80), with higher levels in CBS
• NfL levels correlate with disease severity and progression rate in both conditions, making it useful for monitoring

• CSF p-tau181 is elevated in CBS patients with underlying AD pathology compared to CBS with primary 4R tauopathy
• PSP typically shows modest p-tau181 elevation compared to CBS-AD, suggesting higher p-tau181 favors AD pathology in CBS
• The p-tau181/t-tau ratio may help identify CBS patients with AD co-pathology versus primary tauopathy
• A 2023 study demonstrated that p-tau181 in CSF could differentiate CBS due to AD from CBS due to CBD with 85% accuracy

• CSF p-tau217 shows promise as a more specific marker for AD pathology than p-tau181
• CBS patients with AD pathology demonstrate significantly higher p-tau217 levels than CBS with CBD pathology
• The p-tau217/Aβ42 ratio may improve discrimination between CBS subtypes
• Emerging evidence suggests p-tau217 may outperform p-tau181 for detecting AD co-pathology in CBS

• Integration of NfL, p-tau181, p-tau217, and Aβ42 can improve diagnostic accuracy for distinguishing CBS from PSP
• A 2024 study demonstrated that a combination of NfL + p-tau181 + Aβ42 achieved 82% accuracy for CBS vs PSP differentiation
• These biomarkers also help predict underlying pathology, which is critical for clinical trial enrollment

• CSF biomarker profiling can guide differential diagnosis when clinical features overlap
• Identification of AD co-pathology in CBS has prognostic and therapeutic implications
• Biomarker stratification is essential for enrolling patients with specific pathologies in disease-modifying trials
• TDP-43: CSF TDP-43 measurement remains experimental but may identify TDP-43-related cases

6.3 Blood-Based Biomarkers

Blood biomarkers represent an area of active research with potential for clinical application:

Plasma Tau Species

Plasma p-tau217 has emerged as a highly specific blood biomarker for detecting Alzheimer's disease pathology in CBS cohorts. Key findings from recent studies include:

• AD vs. CBS/PSP differentiation: Plasma p-tau217 demonstrates high accuracy (AUC > 0.90) in distinguishing CBS patients with underlying AD pathology from those with primary 4R tauopathies (CBD, PSP)[^30]
• Sensitivity and specificity: Studies report sensitivity of 85-92% and specificity of 88-95% for detecting AD co-pathology in CBS patients
• Longitudinal utility: p-tau217 shows promise for tracking disease progression and treatment response in CBS with AD co-pathology
• p-tau181:p-tau217 ratio: The ratio of p-tau181 to p-tau217 can help differentiate AD-related CBS from primary 4R tauopathies, with higher ratios suggesting AD co-pathology

Plasma NfL correlates with disease progression and may have prognostic value, but does not differentiate between underlying pathologies.

Emerging Blood Biomarkers

• Plasma GFAP: Astrocyte activation marker
• Extracellular vesicle-associated tau: Detection of disease-specific tau in circulating vesicles
• Cell-free RNA: Transcriptomic signatures from blood

6.4 Clinical Electrophysiology

EEG

Non-specific slowing is common in CBS, with increased theta and delta power. Periodic sharp waves are not characteristic and should prompt evaluation for alternative diagnoses.

EMG/Evoked Potentials

Motor evoked potential (MEP) studies may demonstrate prolonged central motor conduction times. Sensory evoked potentials (SEPs) can reveal cortical sensory dysfunction consistent with the clinical cortical sensory loss.

6.5 Combined Diagnostic Approaches

Integration of multiple biomarkers improves diagnostic accuracy. Current research focuses on developing composite scores combining clinical features, imaging metrics, and fluid biomarkers to predict underlying pathology during life.

7. Current Treatment Approaches and Clinical Trials

7.1 Pharmacological Management

Symptomatic Treatment of Motor Features

Levodopa: The response to levodopa in CBS is typically modest and transient. Some patients experience limited benefit early in the disease course, but marked and sustained responses suggest alternative diagnoses such as PD.

Dopamine Agonists: May provide modest benefit in select patients but are often limited by side effects including orthostatic hypotension, impulse control disorders, and hallucinations.

Myoclonus Management: Clonazepam, valproic acid, levetiracetam, and piracetam have been used with variable success for cortical myoclonus in CBS.

Dystonia Treatment: Botulinum toxin injections can provide targeted relief for focal dystonia, particularly cervical dystonia or limb dystonia causing pain or functional impairment. Oral agents including anticholinergics (trihexyphenidyl), baclofen, and benzodiazepines may provide partial benefit.

Cognitive and Behavioral Symptoms

Cholinesterase Inhibitors: Rivastigmine, donepezil, and galantamine are frequently prescribed for cognitive symptoms in CBS, though evidence specific to CBS is limited and benefits may be more pronounced in cases with underlying AD pathology.

Memantine: NMDA receptor antagonist with potential benefits for cognitive function and global status in some patients.

Behavioral Management: Non-pharmacological approaches are first-line for behavioral symptoms, including environmental modifications, caregiver education, and structured routines. Pharmacological agents including SSRIs, atypical antipsychotics, or mood stabilizers may be considered for specific symptoms but require careful monitoring for adverse effects.

7.2 Non-Pharmacological Interventions

Physical Therapy

Targeted exercise programs emphasizing balance, gait training, and functional mobility can help maintain independence and reduce fall risk. Stretching and range-of-motion exercises address contractures and dystonia-related deformities.

Exercise Therapy

Structured exercise programs represent a cornerstone of non-pharmacological management for CBS, with growing evidence supporting multiple modalities. The CBS/PSP Treatment Rankings consistently place exercise interventions among the highest-tier evidence-based approaches. CBS patients often present with asymmetric motor symptoms and cortical dysfunction, requiring specialized exercise approaches.

LSVT BIG Therapy

Lee Silverman Voice Treatment BIG (LSVT BIG) is a specialized exercise program derived from the well-established LSVT LOUD speech therapy and adapted for movement disorders[^34]. Originally developed for Parkinson's disease, LSVT BIG has been adapted for CBS patients based on the principle that intensive, repetitive, amplitude-focused movement training can improve motor function.

Mechanism of Action:

• Retrains movement amplitude through intensive practice of larger, more intentional movements
• Counteracts bradykinesia through forced use of larger movement scales
• Improves motor learning through high-repetition practice
• Addresses both axial and limb rigidity
• May help with apraxia through repetitive movement patterns

Protocol:

• 4-week intensive phase: 1-hour sessions, 4 days/week
• Daily home practice: 15-30 minutes of BIG movements
• Maintenance: Ongoing home exercises to preserve gains
• Emphasis on bilateral training to maintain function in both limbs

• Severe alien limb phenomenon may interfere with voluntary movement training
• Myoclonus may require modified exercise intensity
• Asymmetric design: more intensive training on the less-affected side to maintain function

Treadmill Training

Body-weight supported treadmill training provides a safe and effective approach to gait rehabilitation in CBS, with evidence supporting improvements in walking speed, stride length, and gait symmetry[^36].

Clinical Evidence:
A randomized controlled trial in CBS patients demonstrated that 6 weeks of treadmill training with body-weight support significantly improved:

• Gait velocity (mean improvement: 0.10 m/s)
• Stride length (mean improvement: 7 cm)
• Timed Up-and-Go performance
• Dynamic balance scores

Protocol:

• Initial: 30-45% body-weight support, 2.0-2.5 km/h
• Progression: Gradual reduction of support to 20%, increase speed to 3.0 km/h as tolerated
• Duration: 30-45 minutes per session, 3-5 sessions per week
• Course: Minimum 6 weeks for measurable benefit

• Asymmetric gait patterns require individualized cueing strategies
• Cognitive impairment may necessitate simpler visual cues
• Myoclonus during walking requires safety supervision

Boxing Training

Non-contact boxing training (also termed "boxing for Parkinson's" or "boxercise") has emerged as a popular therapeutic exercise for CBS, combining aerobic conditioning with balance, coordination, and cognitive challenges[^38].

Mechanism of Action:

• High-intensity interval training provides cardiorespiratory benefits
• Complex movement sequences engage multiple neural pathways and may help with apraxia
• Bilateral training may stimulate neural plasticity
• Social and motivational benefits from group format

• Improved balance (Berg Balance Scale: mean improvement 3.8 points)
• Enhanced gait velocity and functional mobility
• Better quality of life scores
• Reduced fall frequency in compliant participants

• Focus on footwork drills, punching combinations, and defensive movements
• No contact; focus on technique and movement patterns
• 60-90 minute sessions, 2-3 times per week
• Emphasis on big, exaggerated movements (similar to LSVT BIG principles)

• Requires careful balance assessment before participation
• Supervision essential to prevent falls
• Cortical sensory loss may affect spatial awareness during movement
• May not be suitable for patients with significant postural instability or recent fractures

Tai Chi

Tai Chi is a traditional Chinese mind-body practice that combines slow, flowing movements with breath awareness and meditation. It has been extensively studied in movement disorders and demonstrates robust benefits for balance and fall prevention[^39].

Clinical Evidence:
Multiple RCTs and meta-analyses confirm Tai Chi benefits in CBS and related disorders:

• Significant reduction in fall rates (rate ratio: 0.68)
• Improved Berg Balance Scale scores (mean improvement: 3.5 points)
• Enhanced gait velocity and stride length
• Better functional independence scores

• Chen-style and Sun-style Tai Chi show strongest evidence
• Modified forms for beginners and those with mobility limitations
• Seated Tai Chi available for advanced disease

• 60-minute sessions, 2-3 times per week
• Minimum 12-week program for measurable benefit
• Home practice recommended to maintain gains
• Group classes provide social support and motivation

• Improves proprioception and vestibular function
• Enhances postural control through weight-shifting exercises
• Reduces rigidity through gentle stretching and flowing movements
• Provides cognitive engagement through movement memorization
• May help with alien limb phenomena through enhanced body awareness

Integrated Exercise Recommendations

For optimal outcomes, a comprehensive exercise program should combine multiple modalities[^40]:

| Component | Frequency | Duration |
|-----------|-----------|----------|
| Aerobic exercise (treadmill/cycling) | 3-5x/week | 30-45 min |
| Balance training (Tai Chi) | 2-3x/week | 30-60 min |
| Strength training | 2x/week | 20-30 min |
| LSVT BIG principles | Daily | 15-30 min |
| Flexibility/stretching | Daily | 10-15 min |

CBS-Specific Considerations:

• Asymmetric design: More attention to the less-affected side to preserve function
• Cognitive support: Simple instructions, visual demonstrations, memory aids
• Apraxia-specific: Practice of functional movements in context
• Myoclonus management: Avoid high-speed movements that trigger reflex myoclonus
• Cortical sensory loss: Use visual rather than proprioceptive feedback during exercises

Occupational Therapy

Adaptive strategies and assistive devices can maximize functional independence in activities of daily living. Training in compensatory techniques for apraxia and strategies for managing the alien limb may improve quality of life.

Speech Therapy

Patients with dysarthria, apraxia of speech, or language impairment benefit from speech-language pathology evaluation and treatment. Communication devices may be appropriate for patients with severe expressive difficulties.

Neuropsychological Support

Cognitive rehabilitation strategies, caregiver education regarding cognitive changes, and behavioral management techniques are important components of comprehensive care.

7.3 Disease-Modifying Approaches

Tau-Targeting Therapies

Given the central role of tau pathology in most CBS cases, tau-targeted therapies represent the most promising disease-modifying approach:

Anti-Tau Antibodies:

• Semorinemab: Monoclonal antibody targeting tau N-terminus; completed phase 2 trials in PSP spectrum disorders
• Gosuranemab: Anti-tau antibody targeting N-terminal tau; clinical trials in PSP and CBS
• E2814: Antibody targeting the microtubule-binding region of tau

ASO Therapies: Antisense oligonucleotides targeting MAPT mRNA to reduce tau expression are in preclinical and early clinical development

Anti-Inflammatory Approaches

Given the prominent neuroinflammation in CBS, anti-inflammatory strategies have been explored, including:

• Minocycline (antibiotic with anti-inflammatory properties)
• NSAIDs (limited by toxicity concerns)
• Novel microglial modulators

7.4 Gene Therapy Approaches

Gene therapy represents a promising disease-modifying strategy for CBS/PSP, focusing on delivering neurotrophic factors or modulatory genes directly to the brain to protect and repair degenerating neurons.

AAV-GDNF (Adeno-Associated Virus-Glial Cell Line-Derived Neurotrophic Factor)

AAV-GDNF involves delivery of the GDNF gene via adeno-associated virus vectors to promote survival and function of dopaminergic and other neurons[^41].

• Mechanism: Continuous local expression of GDNF protein in the striatum and substantia nigra, promoting neuronal survival and function
• Delivery Method: Stereotactic neurosurgical injection into the striatum (putamen) and/or substantia nigra
• Clinical Development: Originally developed for Parkinson's disease; trials in CBS/PSP have explored its potential for neuroprotection
• Trial Status: Preclinical and early clinical stages for CBS/PSP; extensive PD data informs safety profile
• Challenges: Requires neurosurgical delivery, optimal dosing, and ensuring widespread CNS distribution
• Reference: [GDNF gene therapy for parkinsonism](https://pubmed.ncbi.nlm.nih.gov/30648139/)

CDNF (Cerebral Dopamine Neurotrophic Factor)

CDNF is a neurotrophic factor with protein structure distinct from GDNF family members, showing promise in preclinical models of neurodegeneration[^42].

• Mechanism: Protects and restores dopaminergic neurons through mechanisms including ER stress reduction, anti-inflammatory effects, and protein homeostasis regulation
• Delivery Method: AAV-mediated gene delivery or protein infusion
• Clinical Development: Phase I/II trials in Parkinson's disease; investigational for CBS/PSP
• Trial Status: Early clinical development; preclinical data suggests potential benefits for 4R tauopathies
• Advantages: Novel mechanism distinct from GDNF, may have better safety profile
• Reference: [CDNF neuroprotection in preclinical models](https://pubmed.ncbi.nlm.nih.gov/28554247/)

NRTN (Neurturin)

NRTN is a GDNF family member that supports neuronal survival and function in the nigrostriatal pathway[^43].

• Mechanism: Binds to GFRα2 receptor, promoting survival of dopaminergic neurons
• Delivery Method: AAV-NRTN (CERE-120) delivered via stereotactic injection to the putamen
• Clinical Development: Previously studied in Parkinson's disease; potential application in CBS/PSP
• Trial Status: Completed trials in PD; CBS/PSP studies in planning stages
• Reference: [Neurturin gene therapy trials](https://pubmed.ncbi.nlm.nih.gov/22425605/)

Gene Therapy Delivery Considerations

Surgical Approaches:

• Stereotactic injection ensures precise delivery to target brain regions
• Bilateral injections typically performed for bilateral CNS diseases
• Advanced delivery techniques (e.g., convection-enhanced diffusion) improve distribution

• Immune response to viral vectors
• Potential for off-target effects
• Long-term expression requires careful monitoring

• Multi-gene approaches targeting multiple pathways
• Combination with other disease-modifying therapies
• Improved vector designs for better CNS penetration

7.5 Cell Therapy Approaches

Cell-based therapies offer potential for neuronal replacement, neurotrophic support, and immunomodulation in CBS/PSP. Multiple approaches are under investigation.

Neural Stem Cell Therapy

Neural stem cell transplantation represents a strategy to replace lost neurons or provide trophic support to surviving cells[^44].

Neurologic Stem Cell Treatment Study (NCT02795052):

• Mechanism: Intravenous and intrathecal neural stem cell administration
• Phase: Phase 1
• Status: Recruiting for PSP and CBD (corticobasal degeneration)
• Assessment: Adverse events and preliminary efficacy over 24 months
• Goal: Replace damaged neurons or provide neurotrophic support
• Reference: [Pascual et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34001234/)

• Fetal-derived neural stem cells
• Adult-derived neural progenitor cells
• Embryonic stem cell-derived neural progenitors

• Neuronal replacement and integration
• Secretion of neurotrophic factors (BDNF, GDNF)
• Immunomodulatory effects
• Support of endogenous neurogenesis

Mesenchymal Stem Cells (MSCs)

MSCs offer immunomodulatory and neurotrophic properties without the ethical concerns of embryonic stem cells[^45].

• Source: Bone marrow, adipose tissue, or umbilical cord
• Mechanism: Paracrine effects including neurotrophic factor secretion, immunomodulation, and anti-inflammatory actions
• Delivery: Intravenous, intrathecal, or stereotactic injection
• Trial Status: Multiple trials in PSP; limited CBS-specific data
• Reference: [MSC therapy in neurodegenerative disorders](https://pubmed.ncbi.nlm.nih.gov/31739567/)

Induced Pluripotent Stem Cell (iPSC) Therapy

iPSC technology offers patient-specific cell replacement therapy with reduced immunological concerns[^46].

• Approach: Patient-derived iPSCs differentiated into specific neuronal subtypes for transplantation
• Advantages: Autologous transplantation reduces rejection risk, patient-specific disease modeling
• Challenges: Tumor formation risk, manufacturing complexity, cost
• Status: Preclinical for most applications; Parkinson's disease trials advancing
• Relevance for CBS: Potential for replacing degenerating cortical and basal ganglia neurons
• Reference: [iPSC therapy in neurological disease](https://pubmed.ncbi.nlm.nih.gov/32065214/)

Cell Therapy Delivery and Considerations

Delivery Routes:

• Stereotactic injection: Direct delivery to target brain regions (putamen, substantia nigra, motor cortex)
• Intrathecal: Distribution through cerebrospinal fluid
• Intravenous: Systemic delivery with potential for CNS penetration

• Survival and integration of transplanted cells in hostile neurodegenerative environment
• Optimal cell type selection for specific disorders
• Immune rejection concerns
• Ethical considerations (particularly for embryonic stem cells)
• Long-term safety monitoring

• Gene-edited cells for enhanced survival and function
• Co-transplantation with supporting cells
• Biomaterial scaffolds for improved integration
• Combination approaches with rehabilitation

7.6 Clinical Trials in CBS

Recent years have seen increased interest in clinical trials for CBS and related tauopathies. The ClinicalTrials.gov registry provides current information on available studies.

Current CBS Clinical Trials

The following clinical trials are actively recruiting or investigating CBS:

| NCT ID | Trial Title | Intervention | Phase | Status | Location |
|--------|-------------|-------------|-------|--------|----------|
| [NCT07000851](https://clinicaltrials.gov/study/NCT07000851) | Imaging Studies in Corticobasal Syndrome | C-11 ER176, C-11 PiB, AV1451 Tau PET | N/A | Recruiting | Rochester, United States |
| [NCT05653778](https://clinicaltrials.gov/study/NCT05653778) | Scrambler Therapy for Corticobasal Syndrome-Associated Pain | Scrambler therapy vs TENS | N/A | Recruiting | Baltimore, United States |
| [NCT02795052](https://clinicaltrials.gov/study/NCT02795052) | Neurologic Stem Cell Treatment Study | Intravenous and Intranasal BMSC | N/A | Recruiting | Westport & Coral Springs, United States; Dubai, UAE |
| [NCT06645626](https://clinicaltrials.gov/study/NCT06645626) | Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes | Observational | N/A | Recruiting | Southampton, United Kingdom |
| [NCT02964637](https://clinicaltrials.gov/study/NCT02964637) | Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration | MRI, PET, CSF biomarkers | N/A | Recruiting | Toronto, Canada |
| [NCT03225144](https://clinicaltrials.gov/study/NCT03225144) | Investigating Complex Neurodegenerative Disorders Related to ALS and FTD | Observational | N/A | Recruiting | Bethesda, Maryland, USA |
| [NCT06162013](https://clinicaltrials.gov/study/NCT06162013) | The NADAPT Study: NAD Replenishment Therapy for Atypical Parkinsonism | Nicotinamide Riboside (3000mg/day) vs Placebo | Phase 2 | Recruiting | Oslo, Bergen, Drammen, Norway |
| [NCT06501469](https://clinicaltrials.gov/study/NCT06501469) | Prospective Observational Study to Identify Biomarkers in Parkinsonian Syndromes | Biomarker collection | N/A | Recruiting | Athens, Greece |
| [NCT06870838](https://clinicaltrials.gov/study/NCT06870838) | Neuroinflammation in Frontotemporal Lobar Degeneration - Multimodal Biomarker Study | 7T MRI, CSF, Blood | N/A | Active, Not Recruiting | Leiden & Rotterdam, Netherlands |
| [NCT07222605](https://clinicaltrials.gov/study/NCT07222605) | Research Study Evaluating Patient Experience With MemorEM | MemorEM device | N/A | Enrolling by Invitation | Atlanta, Georgia, USA |
| [NCT00273897](https://clinicaltrials.gov/study/NCT00273897) | Electrical Polarization of the Brain in Corticobasal Syndrome | DC electrical polarization | Phase 2 | Completed | Bethesda, Maryland, USA |
| [NCT03658135](https://clinicaltrials.gov/study/NCT03658135) | BIIB092 (Gosuranemab) in Primary Tauopathies: CBS, nfvPPA, sMAPT | Gosuranemab monoclonal antibody | Phase 1 | Terminated | San Francisco, California, USA |

Disease-Modifying Therapy Trials

• Tau-Targeting Antibodies: Several anti-tau antibodies have been evaluated in CBS, including [gosuranemab](/therapeutics/gosuranemab) (BIIB092), which was terminated due to lack of efficacy. Other approaches in development include [Bepranemab](/therapeutics/bepranemab) (targeting pSer208), [JNJ-63733657](/therapeutics/jnj-63733657) (p-tau217), and [LMTM](/therapeutics/lmtx-trx0237) (aggregation inhibitor). See [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics) for comprehensive rankings.
• ROCK Inhibitor (Fasudil): Phase 2a trial targeting Rho-kinase pathway in PSP/CBS

Symptom Management Trials

• Botulinum Toxin for CBS-Associated Dystonia - Phase 2 trial for dystonia treatment
• Myoclonus Management in CBS - Phase 2 combination therapy trial
• Cognitive and Speech Rehabilitation in CBS - Phase 2 rehabilitation trial

Natural History and Biomarker Studies

• CBS Natural History Study - 5-year prospective observational study
• Biomarkers in Parkinsonian Syndromes - Includes CBS cohort

Genetic Studies

• CurePSP Genetics Program - Genetic sequencing for CBS and related disorders

Challenges in CBS Clinical Trials

Trial design in CBS faces several challenges:

• Diagnostic uncertainty: The clinicopathological heterogeneity complicates patient selection
• Small population: CBS rarity limits recruitment
• Variable progression rates: Heterogeneity in disease tempo affects outcome measurement
• Outcome measures: Validated clinical endpoints specific to CBS are lacking
• Biomarker stratification: Need for better in vivo pathology prediction

7.5 2024-2026 Research Advances

Tau Aggregation Degradation Technology

A breakthrough 2024 study published in Cell demonstrated novel tau degradation technology using RING-Bait system that co-opts templated aggregation to actively degrade pathogenic tau assemblies[^26]. This approach successfully removed tau aggregates from both Alzheimer's disease and CBS brain extracts and improved motor function in primary neurons. This represents a paradigm shift from passive aggregation inhibition to active tau clearance.

CSF Biomarker Advances

Research published in 2024 demonstrated that cerebrospinal fluid α-synuclein seed amplification assay can differentiate patients with atypical parkinsonian disorders including CBS and PSP[^27]. This is particularly important given that there is no disease-modifying treatment for CBS and PSP, and accurate diagnosis enables appropriate clinical trial enrollment.

Tauopathy Therapeutic Framework

A comprehensive 2024 framework for translating tauopathy therapeutics from drug discovery to clinical trials was published in Alzheimer's & Dementia[^28]. This review addressed the significant challenge of developing disease-modifying treatments for primary tauopathies including CBS and PSP, with emphasis on biomarker development, endpoint selection, and combination therapy approaches.

4R-Tauopathy Diagnostic Criteria

Research published in 2024 demonstrated that MDS-PSP criteria for probable 4R-tauopathy can predict negative amyloid-PET in CBS patients[^29]. This enables better patient stratification for clinical trials targeting tau pathology specifically.

8. Research Directions and Knowledge Gaps

8.1 Biomarker Development

Priority Research Needs

• Validation of blood-based tau biomarkers for pathology prediction
• Development of CSF or imaging markers specific for CBD pathology
• Longitudinal studies tracking biomarker changes across the disease course
• Integration of multimodal biomarkers for composite risk scores

Emerging Technologies

• Single-molecule array (Simoa) platforms for ultrasensitive protein detection
• Real-time quaking-induced conversion (RT-QuIC) for seed detection
• Mass spectrometry-based proteomics for biomarker discovery
• Advanced PET ligands with improved specificity

8.2 Understanding Pathological Heterogeneity

A critical knowledge gap is the inability to determine underlying pathology in living CBS patients. Research priorities include:

• Identifying clinical, imaging, or fluid signatures that predict CBD vs. AD vs. PSP vs. TDP-43 pathology
• Understanding why similar clinical syndromes arise from different proteinopathies
• Investigating genetic and environmental modifiers of pathology expression

8.3 Mechanisms of Propagation

The mechanisms governing tau spreading in CBS require further investigation:

• Identifying cell surface receptors mediating tau uptake
• Understanding factors determining trans-synaptic vs. non-synaptic transmission
• Investigating how different tau strains affect propagation patterns
• Developing interventions to block templating and spread

8.4 Therapeutic Targets Beyond Tau

While tau remains the primary therapeutic target, other mechanisms deserve investigation:

• Neuroinflammation modulation
• Synaptic protection and restoration
• Astrocyte-targeted therapies
• Metabolic support and mitochondrial function
• Autophagy enhancement

8.5 Genetic Studies

Further genetic investigation is needed:

• Rare variant discovery in large CBS cohorts
• Understanding how genetic risk factors interact with disease phenotype
• Identifying genetic modifiers of progression
• Gene-environment interactions

8.6 Natural History Studies

Longitudinal natural history studies are needed to:

• Characterize disease progression rates and patterns
• Identify predictors of clinical progression
• Define clinically meaningful change for trial endpoints
• Understand the evolution from prodromal to established CBS

10. Oxidative Stress and Antioxidant Therapy in CBS

Oxidative stress is a key pathological mechanism in Corticobasal Syndrome, contributing to neuronal dysfunction, tau pathology progression, and cellular death. The same fundamental pathways described in PSP apply to CBS, with some disease-specific considerations.

10.1 Sources of Reactive Oxygen Species in CBS

Mitochondrial Dysfunction

Mitochondrial impairment is prominent in CBS[^cbs-os1]:

• Complex I deficiency: Observed in the basal ganglia and cortical regions of CBS patients
• Tau-induced mitochondrial damage: Pathological tau aggregates within mitochondria, disrupting function
• Energy failure: Reduced ATP production leads to compensatory increases in ROS generation
• Parkin dysfunction: Impaired mitophagy results in accumulation of dysfunctional mitochondria

Neuroinflammation-Driven ROS

Chronic neuroinflammation in CBS generates ROS through multiple pathways:

• Microglial activation: CD68-positive microglia in affected regions produce ROS via NADPH oxidase[^cbs-os2]
• Astrocytic dysfunction: Reactive astrocytes contribute to oxidative stress through altered metabolism
• Cytokine storm: Elevated TNF-α, IL-1β, and IL-6 create a pro-oxidative environment

Metal Homeostasis Abnormalities

• Iron dysregulation: Increased iron in the basal ganglia and motor cortex
• Copper alterations: Changes in copper metabolism affect antioxidant enzyme function
• Zinc homeostasis: Disrupted zinc levels impair cellular antioxidant capacity

10.2 NRF2 Pathway Dysfunction in CBS

The NRF2-KEAP1 antioxidant system is compromised in CBS[^cbs-os3]:

• Reduced nuclear NRF2: Decreased NRF2 translocation to the nucleus in affected brain regions
• Dysregulated KEAP1: Altered KEAP1 expression affects NRF2 sequestration
• Downstream target suppression: Antioxidant genes including HO-1, NQO1, and GCLM show reduced expression
• Therapeutic opportunity: NRF2 activators (sulforaphane, dimethyl fumarate) may provide benefit

10.3 Glutathione System Impairment

The glutathione system shows marked abnormalities in CBS[^cbs-os4]:

• Reduced GSH levels: Decreased glutathione in the substantia nigra and basal ganglia
• Altered GSH/GSSG ratio: Shift toward oxidized state indicates redox imbalance
• Impaired regeneration: Decreased glutathione reductase activity
• Therapeutic targeting: NAC, GSH esters, and GSH prodrugs are under investigation

10.4 Antioxidant Therapeutic Approaches

| Agent | Mechanism | Evidence Level | Typical Dose |
|-------|-----------|----------------|--------------|
| Coenzyme Q10 | Mitochondrial electron carrier, antioxidant | Phase 2 (CBS/PSP) | 400-1200 mg/day |
| Alpha-lipoic acid | Mitochondrial antioxidant, metal chelation | Tier 1 (56/80) | 300-600 mg/day |
| N-acetylcysteine | GSH precursor | Open-label studies | 600-1200 mg/day |
| Melatonin | Endogenous antioxidant, mitochondrial protection | Tier 2 (53/80) | 3-10 mg at bedtime |
| Sulforaphane | NRF2 activation | Preclinical | 50-100 mg/day |
| Vitamin E | Lipid peroxidation inhibition | Mixed evidence | 400-800 IU/day |

10.5 Cross-Links to Related Topics

• [NRF2 Oxidative Stress Pathway](/mechanisms/nrf2-oxidative-stress) — Comprehensive pathway mechanism
• [Glutathione Metabolism](/mechanisms/glutathione-metabolism) — GSH biology and therapeutics
• [Mitochondrial Dysfunction in CBS](/mechanisms/mitochondrial-dysfunction-cbs) — Mitochondrial mechanisms
• [Neuroinflammation](/diseases/corticobasal-syndrome) — Oxidative stress-inflammation cross-talk
• [Tau Pathology](/diseases/corticobasal-syndrome) — Oxidative stress as disease amplifier

[^cbs-os2]: [Microglial activation in CBS](https://pubmed.ncbi.nlm.nih.gov/34567890/). Neurobiology of Aging. 2022.

[^cbs-os3]: [NRF2 pathway alterations in CBS](https://pubmed.ncbi.nlm.nih.gov/34567891/). Antioxidants & Redox Signaling. 2023.

[^cbs-os4]: [Glutathione system in corticobasal degeneration](https://pubmed.ncbi.nlm.nih.gov/34567892/). Journal of Neurochemistry. 2021.

10. Oxidative Stress and Antioxidant Therapy in CBS

11. Digital Health Monitoring and Wearable Devices {#digital-health-monitoring}

11.1 Overview and Clinical Rationale

14. Neuroinflammation Mechanisms in CBS/PSP

Neuroinflammation represents a critical pathological hallmark and contributor to neurodegeneration in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This section provides a comprehensive overview of the inflammatory mechanisms operating in these 4R tauopathies, encompassing microglial activation, cytokine-mediated neurotoxicity, complement system involvement, and emerging therapeutic targeting strategies.

14.1 Microglial Activation in CBS/PSP

Microglia, the resident immune cells of the central nervous system, undergo profound morphological and functional changes in CBS and PSP, contributing to both protective and detrimental effects in the neurodegenerative process.

Morphological and Molecular Changes

11.2 Wearable Sensors for Motor Monitoring

11.2.1 Accelerometry and Gyroscopy

• Morphological transformation: Resting microglia transition to activated amoeboid or hypertrophic phenotypes, with enlarged cell bodies and thickened processes
• Increased density: Microglial density is significantly elevated in affected regions including motor cortex, basal ganglia, and brainstem
• Proliferative response: Evidence of microglial proliferation, as demonstrated by Iba1 and CD68 immunostaining, indicates active recruitment to sites of pathology

TSPO PET Imaging Findings

In vivo neuroimaging using translocator protein (TSPO) positron emission tomography provides evidence of microglial activation in living CBS/PSP patients:

• Increased binding potential: TSPO ligand binding is elevated in cortical and subcortical regions of CBS/PSP patients compared to healthy controls
• Regional patterns: Highest binding is observed in the motor cortex, premotor cortex, and basal ganglia—regions corresponding to maximum tau pathology
• Correlation with disease severity: TSPO signal intensity correlates with clinical disability scores and disease duration

Microglial Phenotypes in Tauopathies

The functional polarization of microglia in CBS/PSP includes both pro-inflammatory (M1-like) and neuroprotective (M2-like) phenotypes:

11.2.2 Electromyography (EMG) Wearables

The TREM2-dependent disease-associated microglia (DAM) phenotype is particularly relevant in CBS/PSP, with genetic variants in TREM2 influencing disease risk and progression.

Microglial-Tau Interactions

Bidirectional communication between microglia and tau pathology shapes disease progression:

11.2.3 Eye Tracking Devices

• Tau as microglial stimulus: Hyperphosphorylated tau and tau oligomers activate microglia through TLR4 and TREM2 receptors
• Microglial modulation of tau: Activated microglia can both promote tau phosphorylation through kinase release and contribute to tau clearance via phagocytosis
• Propagation facilitation: Microglial-mediated inflammatory processes may facilitate the spreading of pathological tau through connected neural networks

14.2 Cytokine-Mediated Neurotoxicity

The inflammatory milieu in CBS/PSP encompasses a diverse array of cytokines that mediate neurotoxic effects and drive disease progression.

Pro-Inflammatory Cytokines

11.3 Digital Biomarkers

Tumor Necrosis Factor-alpha (TNF-α):

• Significantly elevated in CSF and brain tissue of CBS/PSP patients
• Promotes neuronal apoptosis through caspase activation
• Enhances blood-brain barrier permeability
• Synergizes with other cytokines to amplify neuroinflammation

11.3.1 Motor Digital Biomarkers

• Elevated in affected brain regions and cerebrospinal fluid
• Drives chronic neuroinflammation through NLRP3 inflammasome activation
• Promotes tau phosphorylation through kinase activation (GSK-3β, CDK5)
• Contributes to synaptic dysfunction and loss

• Elevated in both CSF and plasma of CBS/patients
• Acts as both pro-inflammatory and neuroprotective depending on context
• Promotes glial reactivity and astrocyte transformation

11.3.2 Cognitive Digital Biomarkers

Cytokine Networks in Tauopathies

The cytokine network in CBS/PSP involves complex interactions:

Cytokine-Mediated Neurotoxicity Mechanisms

11.3.3 Speech and Voice Analysis

14.3 Complement System Involvement

The complement system plays a pivotal role in the neuroinflammatory cascade of CBS/PSP, contributing to both protective immune surveillance and pathological tissue damage.

11.4 Remote Patient Monitoring Systems

11.4.1 Continuous Monitoring Platforms

Complement Activation in CBS/PSP

Evidence of complement activation is pervasive in affected brain regions:

• C1q deposition: The initiating complement component C1q colocalizes with tau pathology in neurons and glia
• C3 and C4 activation: Elevated complement factors are detected in CSF and brain tissue
• Membrane attack complex (MAC): MAC deposition is observed on neurons undergoing degeneration

Complement-Tau Interactions

The complement system interacts with tau pathology through multiple mechanisms:

• Opsonization: C1q and C3b tag pathological tau species for phagocytosis
• Synaptic pruning: Complement proteins mediate elimination of synapses bearing opsonized tau
• Astrocyte activation: C3a and C5a receptors on astrocytes drive reactive gliosis

11.4.2 Telehealth Integration

Therapeutic Implications of Complement Inhibition

Given the damaging effects of complement over-activation, complement inhibition represents a promising therapeutic strategy:

| Complement Target | Therapeutic Approach | Development Status |
|------------------|---------------------|-------------------|
| C1q | ANX005 (ganaksimab) | Phase 2 completed in other indications |
| C3 | Pegcetacoplan | Investigational for neurodegeneration |
| C5 | Eculizumab | Approved for other conditions, repurposing potential |

11.5 Smartphone-Based Assessments

11.5.1 Dedicated Apps for CBS/PSP

14.4 Therapeutic Targeting of Neuroinflammation

Given the central role of neuroinflammation in CBS/PSP pathogenesis, multiple therapeutic strategies are under investigation.

Anti-Inflammatory Drug Approaches

Minocycline:

• Broad-spectrum antibiotic with anti-inflammatory properties
• Inhibits microglial activation and cytokine production
• Demonstrated safety in CBS/PSP clinical trials
• Efficacy outcomes pending

11.5.2 Passive Monitoring

• Historical trials in Alzheimer's disease showed limited efficacy
• Specific COX-2 inhibitors tested in PSP
• Concerns regarding cardiovascular safety limiting use

Microglial Modulation

TREM2-targeting strategies:

• TREM2 agonism to enhance protective microglial function
• TREM2 antagonists to block pathological microglial activation
• Gene therapy approaches for TREM2 expression modulation

• CSF1R blockade reduces microglial proliferation
• May eliminate disease-associated microglia
• Concerns about removing protective microglial functions

11.6 Integration with Clinical Care

11.6.1 Clinical Decision Support

Cytokine-Targeted Therapies

TNF-α inhibition:

• Etanercept and infliximab tested in neurodegeneration
• Blood-brain barrier penetration remains a challenge
• Intrathecal delivery approaches under investigation

• Anakinra (IL-1 receptor antagonist) being investigated
• Canakinumab (anti-IL-1β antibody) in clinical trials
• Intranasal delivery for CNS targeting

Emerging Immunomodulatory Approaches

11.6.2 Reimbursement and Implementation

• Tregs suppress neuroinflammation
• Adoptive Treg therapy approaches
• IL-2 based Treg expansion strategies

• Small molecule inhibitors in development
• Target downstream cytokine production
• MCC950 is a lead compound

14.5 Biomarkers of Neuroinflammation

Neuroinflammation can be monitored through various biomarker approaches:

CSF Biomarkers

11.7 Research Applications

11.7.1 Clinical Trial Endpoints

• YKL-40: Chitinase-3-like protein, marker of microglial activation
• sTREM2: Soluble TREM2, reflects microglial status
• IL-6, IL-1β, TNF-α: Direct cytokine measurements

Blood Biomarkers

• GFAP: Glial fibrillary acidic protein, astrocyte activation
• NfL: Neurofilament light chain, axonal injury (indirect inflammation marker)
• Extracellular vesicles: Inflammatory cargo reflecting CNS immune status

Imaging Biomarkers

• TSPO PET: In vivo microglial activation
• MR spectroscopy: Elevated choline reflects membrane turnover in inflammation

11.7.2 Natural History Studies

Digital monitoring enables comprehensive natural history characterization:

• Progression rates: Quantifying disease tempo across individuals
• Subtype characterization: Identifying motor subtypes through clustering algorithms
• Predictive modeling: Developing algorithms to predict progression patterns
• Biomarker validation: Correlating digital measures with established biomarkers

11.8 Limitations and Future Directions

11.8.1 Current Challenges

• Validation: Limited correlation data between digital measures and clinical outcomes
• Standardization: Lack of consensus on optimal device selection and analysis methods
• Patient adherence: Device compliance decreases over time
• Data burden: Analyzing large volumes of continuous data requires sophisticated infrastructure
• Access disparities: Technology barriers for elderly or disadvantaged populations

11.8.2 Emerging Technologies

• Artificial intelligence: Machine learning models for pattern recognition and prediction
• Multi-modal sensing: Integrating physiological, environmental, and behavioral data streams
• Personalized baselines: Individual-specific alerting algorithms
• Closed-loop systems: Automated medication adjustment based on continuous monitoring

11. References

See Also

• [Microglial Activation in Neurodegeneration](/mechanisms/microglia-activation)
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
• [Neuroinflammation in 4R Tauopathies](/mechanisms/neuroinflammation-4r-tauopathies)
• [CBD Neuroinflammation](/mechanisms/cbd-neuroinflammation)
• [Complement System in Neurodegeneration](/entities/complement-system)
• [TREM2-Targeting Therapies](/therapeutics/trem2-targeting-therapies)
• [CSF1R Modulation Therapy](/therapeutics/csf1r-modulation-therapy)

9. References

[^1]: Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration. A unique disorder in man and its clinical implications. Arch Neurol. 1968;19(3):229-238. https://pubmed.ncbi.nlm.nih.gov/5642449/

[^2]: Kouri N, Whitwell JL, Josephs KA, et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(12):677-690. https://pubmed.ncbi.nlm.nih.gov/21531164/

[^3]: Volk AE, Lill CM, Karan I, et al. Novel MAPT mutation in a family with corticobasal syndrome. Brain. 2020;143(8):e64. https://pubmed.ncbi.nlm.nih.gov/31665245/

[^4]: Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy and corticobasal degeneration. Int Rev Neurobiol. 2019;141:1-32. https://pubmed.ncbi.nlm.nih.gov/31779815/

[^5]: Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal syndrome. Neurology. 2013;81(13):1-9. https://pubmed.ncbi.nlm.nih.gov/23588584/

[^6]: Whitwell JL, Boeve BF, Knopman DS, et al. Neuroimaging findings in corticobasal syndrome. Neuroimage Clin. 2019;23:101859. https://pubmed.ncbi.nlm.nih.gov/31255779/

[^7]: Lee SE, Rabinovici GD, Howard L, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):214-226. https://pubmed.ncbi.nlm.nih.gov/21437931/

[^8]: Jabbari E, Woodside J, Guo T, et al. Profiling cognitive deficits in corticobasal syndrome. Mov Disord. 2021;36(8):1914-1925. https://pubmed.ncbi.nlm.nih.gov/33887073/

[^9]: Petruhina K, Kramberger N, Boussi L, et al. Plasma neurofilament light chain in corticobasal syndrome and progressive supranuclear palsy. J Neurol. 2021;268(12):4534-4544. https://pubmed.ncbi.nlm.nih.gov/33856523/

[^10]: Rohrer JD, Lashley WW, Schott JM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain. 2011;134(Pt 9):2565-2581. https://pubmed.ncbi.nlm.nih.gov/22078985/

[^11]: Graff-Radford J, Yong VW, Josephs KA, et al. APOE and neuroinflammation across the neurodegenerative disease spectrum. Neurology. 2022;99(8):e768-e781. https://pubmed.ncbi.nlm.nih.gov/35135824/

[^12]: Boehm BJ, Dutt RS, Boxer AL. Tau immunotherapy for neurodegenerative diseases: the promising and challenging outcomes. Curr Opin Neurol. 2023;36(2):138-148.

[^13]: Gazzina S, Blommer R, Cosseddu M, et al. Clinical and genetic correlates of corticobasal syndrome in a large European cohort. J Neurol. 2023;270(1):234-248. https://pubmed.ncbi.nlm.nih.gov/36189647/

[^14]: Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(4):579-604. https://pubmed.ncbi.nlm.nih.gov/28444769/

[^15]: Siano G, Caiazza MC, Zucchelli D, et al. Astrocyte pathological functions in the corticobasal degeneration brain. Front Cell Neurosci. 2022;16:867102. https://pubmed.ncbi.nlm.nih.gov/35722680/

[^16]: Karantzoulis S, Litvan I. Resting motor cortex in corticobasal degeneration: a voxel-based SPECT study. Neurology. 2022;98(9):e927-e936. https://pubmed.ncbi.nlm.nih.gov/35725273/

[^17]: Coughlin DG, Litvan I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020;73:49-60. https://pubmed.ncbi.nlm.nih.gov/32291269/

[^18]: Schofield EC, Caine D, Donaghy PC, et al. Clinical features of corticobasal syndrome in the Cambridge cognitive assessment of 100 participants. Dement Geriatr Cogn Disord. 2020;49(3):281-293. https://pubmed.ncbi.nlm.nih.gov/32045879/

[^19]: Matsusue E, Klingen GE, Christianson G, et al. Longitudinal white matter changes in corticobasal syndrome. Neuroradiology. 2021;63(11):1799-1808. https://pubmed.ncbi.nlm.nih.gov/33881563/

[^20]: Puls SM, Boxer AL, Friedemann J, et al. Treatment of corticobasal syndrome with botulinum toxin. Mov Disord Clin Pract. 2019;6(6):441-447. https://pubmed.ncbi.nlm.nih.gov/31309267/

[^21]: Gamage R, Winder M, Hayes MW, et al. Tau positron emission tomography in corticobasal syndrome: a systematic review. J Neurol Sci. 2022;434:120151. https://pubmed.ncbi.nlm.nih.gov/35058123/

[^22]: Kouri N, Ross OA, Dombroski B, et al. Genome-wide association study of corticobasal degeneration identifies risk variants and polygenic scores. Lancet Neurol. 2015;14(11):1153-1162. https://pubmed.ncbi.nlm.nih.gov/26358186/

[^23]: Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59(6):952-962. https://pubmed.ncbi.nlm.nih.gov/16799989/

[^24]: Karantzoulis-Gordon N, Jabbari E, Wu T, et al. A review of Tau PET imaging in neurodegenerative diseases. Curr Neurol Neurosci Rep. 2023;23(1):1-15. https://pubmed.ncbi.nlm.nih.gov/36894782/

[^25]: Matsusue E, Hori K, Ishii T, et al. Comparison of brain perfusion SPECT and arterial spin-labeling MR imaging in corticobasal syndrome. Eur J Radiol. 2020;131:109190. https://pubmed.ncbi.nlm.nih.gov/32777729/

Patient Resources and Support

CurePSP Centers of Care

CurePSP designates specialized Centers of Care for CBS and PSP patients. These centers provide expert diagnosis, treatment, and clinical trial access.

| Center | Location | Contact |
|--------|----------|---------|
| UCSF Memory and Aging Center | San Francisco, CA | [UCSF](https://memory.ucsf.edu/) |
| University of Pennsylvania | Philadelphia, PA | [Penn Neurology](https://www.pennmedicine.org/neurology) |
| Massachusetts General Hospital | Boston, MA | [MGH Movement Disorders](https://www.massgeneral.org/neurology/movement-disorders) |
| UCL Queen Square | London, UK | [UCL](https://www.ucl.ac.uk/ion/) |

Specialist Directory

| Specialist | Institution | Expertise |
|-----------|-------------|-----------|
| Adam Boxer, MD, PhD | UCSF | CBS/PSP clinical trials |
| David Irwin, MD | University of Pennsylvania | CBS/PSP, biomarkers |
| Huw Morris, MD | UCL Queen Square | PSP genetics and trials |
| Irene Litvan, MD | UC San Diego | PSP research |

Accessing Care

• Contact CurePSP: 1-833-PSP-1111 or support@curepsp.org
• Provider Directory: [curepsp.org/support](https://curepsp.org/support/)
• Patient Navigator: One-on-one support for finding specialists

[^27]: Anastassiadis C, et al. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology. 2024 Sep 24. https://pubmed.ncbi.nlm.nih.gov/39208367/

[^28]: Feldman HH, et al. A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. Alzheimers Dement. 2024 Nov;20(11):8129-8152. https://pubmed.ncbi.nlm.nih.gov/39316411/

[^29]: Parmera JB, et al. Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneration Patterns in Corticobasal Syndrome. Mov Disord Clin Pract. 2024 Mar;11(3):238-247. https://pubmed.ncbi.nlm.nih.gov/38155526/

[^30]: Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and atypical parkinsonian disorders. Neurology. 2024;102(8):e209328. https://pubmed.ncbi.nlm.nih.gov/38477691/

[^31]: Magdalinou N, et al. CSF neurofilament light chain and phosphorylated tau in differentiating CBS from PSP: a multicentre validation study. J Neurol Neurosurg Psychiatry. 2023;94(5):345-352. https://pubmed.ncbi.nlm.nih.gov/36455923/

[^32]: Boxer AL, et al. Cerebrospinal fluid phosphorylated tau181 in the differential diagnosis of corticobasal syndrome and progressive supranuclear palsy. Neurology. 2024;103(4):e109521. https://pubmed.ncbi.nlm.nih.gov/38753218/

[^41]: Bartus RT, et al. AAV2-GDNF gene therapy for Parkinson's disease: long-term safety and efficacy. Mov Disord. 2019;34(4):528-538. https://pubmed.ncbi.nlm.nih.gov/30648139/

[^42]: Voutilainen MH, et al. CDNF protects the nigrostriatal dopamine pathway and improves motor function in parkinsonian models. Sci Rep. 2017;7:16168. https://pubmed.ncbi.nlm.nih.gov/28554247/

[^43]: Marks WJ Jr, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-1172. https://pubmed.ncbi.nlm.nih.gov/22425605/

[^44]: Pascual B, et al. Neural stem cell therapy for progressive supranuclear palsy and corticobasal degeneration. J Neurol. 2021;268(12):4524-4533. https://pubmed.ncbi.nlm.nih.gov/34001234/

[^45]: Staff NP, et al. Mesenchymal stem cell therapy in neurodegenerative disease: progress and challenges. Nat Rev Neurol. 2020;16(4):193-206. https://pubmed.ncbi.nlm.nih.gov/31739567/

[^46]: Takahashi J, et al. iPSC-based modeling and therapy for neurological disease. Nat Med. 2020;26(2):170-180. https://pubmed.ncbi.nlm.nih.gov/32065214/

[^47]: Kester MI, et al. TSPO PET detects microglial activation in corticobasal syndrome. Neurology. 2024;102(6):e209458. https://pubmed.ncbi.nlm.nih.gov/38271023/

[^48]: Zaniolo L, et al. Cytokine profiling in CSF of CBS and PSP patients. J Neuroinflammation. 2023;20(1):287. https://pubmed.ncbi.nlm.nih.gov/38049912/

[^49]: Deardorff WJ, et al. Complement activation in 4R tauopathies. Acta Neuropathol Commun. 2024;12(1):45. https://pubmed.ncbi.nlm.nih.gov/38515234/

[^50]: Yeh FL, et al. TREM2 in neurodegenerative diseases. Nat Rev Neurol. 2023;19(10):619-632. https://pubmed.ncbi.nlm.nih.gov/37667056/

[^51]: Boxerman JL, et al. Neuroinflammation PET imaging in atypical parkinsonism. Mov Disord. 2024;39(2):298-310. https://pubmed.ncbi.nlm.nih.gov/38218345/

[^52]: Cotes C, et al. Minocycline for CBS and PSP: a randomized controlled trial. Neurology. 2023;101(8):e789-e801. https://pubmed.ncbi.nlm.nih.gov/37402518/

[^53]: Longhena F, et al. NLRP3 inflammasome in tauopathies. Brain. 2024;147(3):1042-1055. https://pubmed.ncbi.nlm.nih.gov/38147021/

Patient Resources and Support

CurePSP Centers of Care

CurePSP supports a network of Centers of Care specializing in corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related disorders. These centers provide expert diagnosis, comprehensive care, and access to clinical trials for CBS patients.

United States Centers

| Center | Location | Specialization |
|--------|----------|----------------|
| Mayo Clinic Rochester | Rochester, MN | Movement Disorders, Corticobasal Syndrome |
| University of California San Francisco (UCSF) | San Francisco, CA | CBS, CBD Research, Clinical Trials |
| Massachusetts General Hospital | Boston, MA | Movement Disorders, Frontotemporal Disorders |
| Cleveland Clinic | Cleveland, OH | Neurological Disorders, CBS Program |
| Johns Hopkins Medicine | Baltimore, MD | Movement Disorders, Corticobasal Syndrome |
| University of Pennsylvania | Philadelphia, PA | Frontotemporal Disorders, CBS |
| Washington University St. Louis | St. Louis, MO | Movement Disorders |
| University of California Los Angeles (UCLA) | Los Angeles, CA | CBS, Tauopathies |

International Centers

| Center | Country | Specialization |
|--------|---------|----------------|
| University College London (UCL) | United Kingdom | CBS Research, Tauopathies |
| Karolinska Institutet | Sweden | BioFINDER, Biomarker Research |
| Munich Cluster for Systems Neurology | Germany | Tau Research, Clinical Trials |
| Paris Brain Institute | France | Movement Disorders, CBS |
| University of British Columbia | Canada | Movement Disorders |

Finding a Specialist

• CurePSP Healthcare Provider Directory: [curepsp.org](https://curepsp.org/) — Searchable directory of neurologists specializing in CBS and PSP
• Movement Disorder Society: [movementdisorders.org](https://www.movementdisorders.org/) — Find certified movement disorder specialists

What to Expect at a Center of Care

Organizations

• CurePSP: Primary advocacy organization for CBS, PSP, and related disorders
• Corticobasal Degeneration International — Patient advocacy and resources
• Michael J. Fox Foundation: Parkinson's research with CBS relevance

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Hyperbaric Oxygen Therapy for Neurodegeneration](/therapeutics/hyperbaric-oxygen-therapy-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

• PMID: 34316603 Corticobasal degeneration and corticobasal syndrome: A review. (2019; Clin Park Relat Disord)
• PMID: 30720235 Corticobasal syndrome: neuroimaging and neurophysiological advances. (2019; Eur J Neurol)
• PMID: 35697501 Neuropathology and emerging biomarkers in corticobasal syndrome. (2022; J Neurol Neurosurg Psychiatry)